×
Brain Inflammation Seen for First Time in Fibromyalgia
https://www.medscape.com/viewarticle/904827

Nov 12th, 2018 - Researchers have reported for the first time that they have found inflammation in the brains of patients with fibromyalgia. Daniel S. Albrecht, PhD, a postdoctoral fellow with the Department of Radiology at Massachusetts General Hospital, and Harvard Medical School, Boston, and colleagues, joined with a research team led by Anton Forsberg, PhD, of the Department of Clinical Neuroscience at the ...

Earlier treatment with baricitinib improves onset of efficacy
https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7B166baf7c-10db-45a9-9903-51185c37cc89%7D/earlier-treatment-with-baricitinib-improves-onset-of-efficacy

Nov 12th, 2018 - Patients with moderate to severe rheumatoid arthritis experienced onset of efficacy sooner when treatment with baricitinib started earlier vs. later, although improvement in overall disease activity was similar among patients who received earlier vs. later treatment, according to findings presented at the ACR/ARHP 2018 Annual Meeting.

ACR forges ahead with physician-focused APM for RA
https://www.mdedge.com/rheumatology/article/184159/rheumatoid-arthritis/acr-forges-ahead-physician-focused-apm-ra
Jeff Evans

Nov 9th, 2018 - CHICAGO – The American College of Rheumatology is continuing to work on its physician-focused advanced alternative payment model (APM) pathway for RA, with hopes to send the fully developed model to the Physician-Focused Payment Model Technical Advisory Committee once financial data gathering and analysis is complete, followed by pilot testing once it is accepted by the Centers for Medicare & M.

COAST-V: Ixekizumab improves AS symptoms
https://www.healio.com/rheumatology/spondyloarthropathies/news/online/%7Bc6ef95a5-6f91-4fea-8771-1ad314ea6080%7D/coast-v-taltz-improves-ankylosing-spondylitis-symptoms

Nov 9th, 2018 - Ixekizumab was superior to placebo in reducing disease activity while improving function, as well as spinal and sacroiliac joint

MBDA score predicts, tracks RA patients’ responses to tofacitinib and rituximab
https://www.mdedge.com/internalmedicine/article/184003/rheumatoid-arthritis/mbda-score-predicts-tracks-ra-patients
Sharon Worcester

Nov 7th, 2018 - CHICAGO – The commercially available multibiomarker disease activity score assay and power Doppler ultrasound at baseline in rheumatoid arthritis patients treated with tofacitinib predicted 12-week responses on some clinical, imaging, and biomarker endpoints, according to findings from an investigator-initiated, open-label study. Dr.

Draft JIA recommendations from ACR seek inactive disease
https://www.mdedge.com/rheumatology/article/183982/pediatrics/draft-jia-recommendations-acr-seek-inactive-disease
Mitchel L. Zoler

Nov 7th, 2018 - CHICAGO – New draft guidelines for treating juvenile idiopathic arthritis (JIA) written by experts assembled by the American College of Rheumatology “formalize inactive disease as the goal of treatment,” Timothy G. Beukelman, MD, said at the annual meeting of the American College of Rheumatology.

Study confirms advice to halt methotrexate when giving flu vaccine to RA patients
https://www.mdedge.com/internalmedicine/article/183943/rheumatoid-arthritis/study-confirms-advice-halt-methotrexate-when
Bruce Jancin

Nov 7th, 2018 - CHICAGO – Discontinuing methotrexate for 2 weeks in patients with RA starting the day they receive the seasonal influenza vaccine significantly improves the vaccine’s immunogenicity without aggravating disease activity, Kevin L. Winthrop, MD, reported at the annual meeting of the American College of Rheumatology.

Genetic profile flags scleroderma patients with best HSCT responses
https://www.mdedge.com/internalmedicine/article/183931/lupus-connective-tissue-diseases/genetic-profile-flags-scleroderma
Mitchel L. Zoler

Nov 6th, 2018 - CHICAGO – Subgroup categorization of patients with severe scleroderma by their gene-expression profile correlated with responses to a newly proven treatment for the disease that involves myeloablation and autologous hematopoietic stem cell transplantation (HSCT). Dr.

Dueling SLE classification criteria: And the winner is...
https://www.mdedge.com/internalmedicine/article/183909/lupus-connective-tissue-diseases/dueling-sle-classification-criteria
Bruce Jancin

Nov 6th, 2018 - CHICAGO – Newer isn’t necessarily better – especially when it comes to the plethora of SLE classification criteria, according to Michelle A. Petri, MD, professor of medicine and director of the Hopkins Lupus Center at Johns Hopkins University, Baltimore.

Culturally competent' online resource raises lupus awareness in at-risk populations
https://www.healio.com/rheumatology/lupus/news/online/%7Bd73ed60a-ef65-4086-b9b7-4f0ad020d4a8%7D/culturally-competent-online-resource-raises-lupus-awareness-in-at-risk-populations

Nov 6th, 2018 - A “culturally competent” and well-designed online resource, called “Be Fierce. Take Control,” was successful in raising awareness of systemic lupus erythematosus among at-risk populations, including young black and Latina women, according to data presented at the ACR/ARHP 2018 Annual Meeting by R. Paola Daly, MPH, of the Lupus Foundation of America

Ixekizumab Improves Outcomes of Ankylosing Spondylitis
https://www.medscape.com/viewarticle/904323

Nov 5th, 2018 - NEW YORK (Reuters Health) - Ixekizumab improves signs and symptoms in patients with radiographic axial spondyloarthritis (ankylosing spondylitis), according to results from the COAST-W study. "Ankylosing spondylitis is a chronic and debilitating disease, and I have a large number of patients who have failed TNF inhibitors," said Dr. Atul Deodhar from Oregon Health and Science University, in Por...